ScholarWorks@SOONCHUNHYANG UNIVERSITY

Detailed Information

Cited 0 time in webofscience Cited 37 time in scopus
Metadata Downloads

New feasible treatment for refractory autoimmune encephalitis: Low-dose interleukin-2

Full metadata record
DC Field Value Language
dc.contributor.authorLim, Jung-Ah-
dc.contributor.authorLee, Soon-Tae-
dc.contributor.authorMoon, Jangsup-
dc.contributor.authorJun, Jin-Sun-
dc.contributor.authorPark, Byeong-su-
dc.contributor.authorByun, Jung-Ick-
dc.contributor.authorSunwoo, Jun-Sang-
dc.contributor.authorPark, Kyung-Il-
dc.contributor.authorJung, Keun-Hwa-
dc.contributor.authorJung, Ki-Young-
dc.contributor.authorLee, Sang Kun-
dc.contributor.authorChu, Kon-
dc.date.accessioned2021-08-11T16:45:19Z-
dc.date.available2021-08-11T16:45:19Z-
dc.date.issued2016-10-15-
dc.identifier.issn0165-5728-
dc.identifier.issn1872-8421-
dc.identifier.urihttps://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8674-
dc.description.abstractLow-dose interleukin-2 (IL-2) restores the balance of regulatory and effector T cells. We aimed to determine the feasibility of low-dose IL-2 as a treatment for refractory autoimmune encephalitis (AE). Ten patients who had received low-dose IL-2 were retrospectively identified. We observed an improvement in the modified Rankin Scale scores of six patients at the last follow-up compared with the scores at the initiation of low-dose IL-2 (p = 0.014). One patient experienced treatment-related grade 3 neutropenia. Overall, low-dose IL-2 is a feasible and relatively safe treatment for AE patients who are refractory to the first- and second-line immunotherapies. (C) 2016 Elsevier B.V. All rights reserved.-
dc.format.extent5-
dc.language영어-
dc.language.isoENG-
dc.publisherElsevier BV-
dc.titleNew feasible treatment for refractory autoimmune encephalitis: Low-dose interleukin-2-
dc.typeArticle-
dc.publisher.location네델란드-
dc.identifier.doi10.1016/j.jneuroim.2016.09.001-
dc.identifier.scopusid2-s2.0-84987943170-
dc.identifier.wosid000386190900017-
dc.identifier.bibliographicCitationJournal of Neuroimmunology, v.299, pp 107 - 111-
dc.citation.titleJournal of Neuroimmunology-
dc.citation.volume299-
dc.citation.startPage107-
dc.citation.endPage111-
dc.type.docTypeArticle-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClasssci-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaImmunology-
dc.relation.journalResearchAreaNeurosciences & Neurology-
dc.relation.journalWebOfScienceCategoryImmunology-
dc.relation.journalWebOfScienceCategoryNeurosciences-
dc.subject.keywordPlusREGULATORY T-CELLS-
dc.subject.keywordPlusNMDA-RECEPTOR ENCEPHALITIS-
dc.subject.keywordPlusMULTIPLE-SCLEROSIS-
dc.subject.keywordPlusTOLERANCE-
dc.subject.keywordPlusDISEASES-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordPlusPREVALENCE-
dc.subject.keywordPlusACTIVATION-
dc.subject.keywordPlusANTIBODIES-
dc.subject.keywordPlusINDUCTION-
dc.subject.keywordAuthorEncephalitis-
dc.subject.keywordAuthorAutoimmune encephalitis-
dc.subject.keywordAuthorLow-dose IL-2-
dc.subject.keywordAuthorRegulatory T cell-
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Neurology > 1. Journal Articles
Show simple item record

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

STATISTICS
Total View :1,397,917
Today View :2,516

RSS_1.0 RSS_2.0 ATOM_1.0

CONTACT US

(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114

COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어